Clinical Trial

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

Name: A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN) — clinical trial record (NCT07288567)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

Protocol Amendment History 2 changes

notable Trial sites reduced: 44 -> 39 locations 2026-07-21

notable Trial sites expanded: 41 -> 44 locations 2026-07-01

Trial Details

NCT Number	NCT07288567
Lead Sponsor	Bristol-Myers Squibb
Conditions	Schizophrenia
Enrollment	166 participants
Start Date	2026-01-29
Primary Completion	2029-12-18 (estimated)
Study Completion	2029-12-18 (estimated)
Updated on ClinicalTrials.gov	2026-08-13